MedTrace Logo

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

NCT00038636 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2006-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

Conditions

  • HIV Infections

Interventions

DRUG

Lopinavir/ritonavir

DRUG

Ritonavir

Sponsors & Collaborators

Principal Investigators

  • Eugene Sun, M.D. · Divisional Vice President, Infectious Diseases and Virology Dept.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038636 on ClinicalTrials.gov